Subscribe To
Founders fund backed jennifer campbell's startup before she sold it to coinbase for millions. now she's looking to 'harpoon' a startup 'whale' as the firm's newest partner.
Jennifer Campbell left Coinbase to become a partner at Founders Fund. She's a rare generalist investor looking for "super audacious ideas" across sec...
October 26, 2023, 6:00 am
harpoon therapeutics stock soars on ‘promising' lung cancer drug results
harpoon Therapeutics Inc shares surged as much as 40% in pre-market trading on Monday after the clinica...
October 23, 2023, 9:32 am
harpoon therapeutics announces updated interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023
Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete re...
October 21, 2023, 3:31 pm
harpoon therapeutics to present interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- harpoon Therapeutics, Inc. (Nasdaq: HAR...
October 9, 2023, 4:17 pm
Boeing (ba) wins contract to support harpoon missile systems
Boeing (BA) secures an $11.5-million contract to support harpoon Coastal Defense Cruise Missile systems...
October 6, 2023, 9:01 am
harpoon therapeutics announces first patients with small cell lung cancer dosed in hpn328 combination cohort
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) — harpoon Therapeutics, Inc. (Nasdaq: HA...
September 15, 2023, 11:15 am
harpoon therapeutics abstract for hpn217 accepted for poster presentation at the 20th international myeloma society annual meeting
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — harpoon Therapeutics, Inc. (Nasdaq: HA...
September 6, 2023, 11:30 am
harpoon therapeutics to host kol event in person and via webcast on september 15, 2023
KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors Abstract with HPN328 interim data accepted for p...
September 5, 2023, 8:05 am
Boeing (ba) wins contract to support harpoon missile system
The Boeing Company BA recently clinched a contract involving its harpoon missiles. The award has been o...
August 23, 2023, 10:31 am
Boeing (ba) secures contract to repair harpoon missiles
Boeing (BA) is set to provide for the rework, repair and overhaul of 16 harpoon capsules and six all-up...
August 16, 2023, 11:44 am
harpoon therapeutics reports first quarter 2023 financial results and provides corporate update
Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical...
May 11, 2023, 8:30 pm
Boeing (ba) wins $1.2b deal to supply missiles & spare parts
Boeing (BA) will supply 400 RGM-84L-4 harpoon Block II Update (HIIU) Grade B canister tactical missiles...
April 13, 2023, 9:54 am
Why fast-paced mover harpoon therapeutics, inc. (harp) is a great choice for value investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, ...
January 25, 2023, 10:33 am
harpoon therapeutics remains volatile after promising news
harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intr...
December 14, 2022, 1:01 am
harpoon therapeutics presents updated interim results at ash 2022 for novel t cell engager hpn217 in relapsed/refractory multiple myeloma
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma...
December 11, 2022, 3:00 pm
harpoon therapeutics to present interim results from phase 1 clinical trial of t cell engager hpn217 at the 64th ash annual meeting and exposition
Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma to be presented...
November 3, 2022, 9:09 am
harpoon therapeutics: a well undervalued tri-specific oncology player
harpoon Therapeutics is an oncology platform play developing tri-specific drug candidates. The company'...
September 1, 2022, 5:17 am
harpoon therapeutics, inc. (harp) reports q2 loss, misses revenue estimates
harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 3.64% and 9.95%, respecti...
August 10, 2022, 6:48 pm
harpoon therapeutics: a t-cell engager platform and a negative enterprise value makes it a candidate for my 'bio boom' portfolio
harpoon Therapeutics has an intriguing platform that can generate stable bispecific immunotherapies usi...
July 7, 2022, 5:34 pm
harpoon therapeutics, inc. (harp) reports q1 loss, misses revenue estimates
harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -29.17% and 47.76%, respe...
May 12, 2022, 6:48 pm